Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines

Autores
Isnardi, Carolina A.; Cerda, Osvaldo L.; Landi, Margarita; Cruces, Leonel Hernán; Schneeberger, Emilce E.; Montoro, Claudia Calle; Alfaro, María Agustina; Roldán, Brian M.; Gómez Vara, Andrea B.; Giorgis, Pamela; Ezquer, Roberto Alejandro; Crespo Rocha, María G; Reyes Gómez, Camila R.; de Los Ángeles Correa, Mária; Rosemffet, Marcos G.; Abarza, Virginia Carrizo; Pellet, Santiago Catalan; Perandones, Miguel; Reimundes, Cecilia; Longueira, Yesica Soledad; Turk, Gabriela Julia Ana; Quiroga, María Florencia; Laufer, Natalia Lorna; Quintana, Rosana Maris; de la Vega, María Celina; Kreplak, Nicolás; Pifano, Marina; Maid, Pablo; Pons Estel, Guillermo J.; Citera, Gustavo
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Objective. The aim of this study was to assess the immune response after a third dose of SARS-CoV-2 vaccine in patients with rheumatoid arthritis (RA) with undetectable antibody titers after the primary regimen of 2 doses. Methods. Patients with RA with no seroconversion after 2 doses of SARS-CoV-2 vaccine and who received a third dose of either an mRNA or vector-based vaccine were included. Anti-SARS-CoV-2 IgG antibodies, neutralizing activity, and T cell responses were assessed after the third dose. Results. A total of 21 nonresponder patients were included. At the time of vaccination, 29% were receiving glucocorticoids and 85% biologic disease-modifying antirheumatic drugs (including 6 taking abatacept [ABA] and 4 taking rituximab [RTX]). The majority (95%) received the BNT162b2 vaccine and only one of them received the ChAdOx1 nCoV-19 vaccine. After the third dose, 91% of the patients presented detectable anti-SARS-CoV-2 IgG and 76% showed neutralizing activity. Compared to other treatments, ABA and RTX were associated with the absence of neutralizing activity in 4 out of 5 (80%) patients and lower titers of neutralizing antibodies (median 3, IQR 0-20 vs 8, IQR 4-128; P = 0.20). Specific T cell response was detected in 41% of all patients after the second dose, increasing to 71% after the third dose. The use of ABA was associated with a lower frequency of T cell response (33% vs 87%, P = 0.03). Conclusion. In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.
Fil: Isnardi, Carolina A.. No especifíca;
Fil: Cerda, Osvaldo L.. No especifíca;
Fil: Landi, Margarita. Austral University Hospital; Liberia
Fil: Cruces, Leonel Hernán. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Schneeberger, Emilce E.. No especifíca;
Fil: Montoro, Claudia Calle. Austral University Hospital; Liberia
Fil: Alfaro, María Agustina. No especifíca;
Fil: Roldán, Brian M.. No especifíca;
Fil: Gómez Vara, Andrea B.. No especifíca;
Fil: Giorgis, Pamela. No especifíca;
Fil: Ezquer, Roberto Alejandro. No especifíca;
Fil: Crespo Rocha, María G. No especifíca;
Fil: Reyes Gómez, Camila R.. No especifíca;
Fil: de Los Ángeles Correa, Mária. No especifíca;
Fil: Rosemffet, Marcos G.. No especifíca;
Fil: Abarza, Virginia Carrizo. No especifíca;
Fil: Pellet, Santiago Catalan. Austral University Hospital; Liberia
Fil: Perandones, Miguel. No especifíca;
Fil: Reimundes, Cecilia. Austral University Hospital; Liberia
Fil: Longueira, Yesica Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Turk, Gabriela Julia Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Quiroga, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Laufer, Natalia Lorna. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Quintana, Rosana Maris. No especifíca;
Fil: de la Vega, María Celina. No especifíca;
Fil: Kreplak, Nicolás. No especifíca;
Fil: Pifano, Marina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Maid, Pablo. Austral University Hospital; Liberia
Fil: Pons Estel, Guillermo J.. No especifíca;
Fil: Citera, Gustavo. No especifíca;
Materia
ARGENTINA
COVID-19
RHEUMATOID ARTHRITIS
SARS-COV-2
VACCINES
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/212994

id CONICETDig_74438af6bd4f84fb6051927947950ded
oai_identifier_str oai:ri.conicet.gov.ar:11336/212994
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based VaccinesIsnardi, Carolina A.Cerda, Osvaldo L.Landi, MargaritaCruces, Leonel HernánSchneeberger, Emilce E.Montoro, Claudia CalleAlfaro, María AgustinaRoldán, Brian M.Gómez Vara, Andrea B.Giorgis, PamelaEzquer, Roberto AlejandroCrespo Rocha, María GReyes Gómez, Camila R.de Los Ángeles Correa, MáriaRosemffet, Marcos G.Abarza, Virginia CarrizoPellet, Santiago CatalanPerandones, MiguelReimundes, CeciliaLongueira, Yesica SoledadTurk, Gabriela Julia AnaQuiroga, María FlorenciaLaufer, Natalia LornaQuintana, Rosana Marisde la Vega, María CelinaKreplak, NicolásPifano, MarinaMaid, PabloPons Estel, Guillermo J.Citera, GustavoARGENTINACOVID-19RHEUMATOID ARTHRITISSARS-COV-2VACCINEShttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Objective. The aim of this study was to assess the immune response after a third dose of SARS-CoV-2 vaccine in patients with rheumatoid arthritis (RA) with undetectable antibody titers after the primary regimen of 2 doses. Methods. Patients with RA with no seroconversion after 2 doses of SARS-CoV-2 vaccine and who received a third dose of either an mRNA or vector-based vaccine were included. Anti-SARS-CoV-2 IgG antibodies, neutralizing activity, and T cell responses were assessed after the third dose. Results. A total of 21 nonresponder patients were included. At the time of vaccination, 29% were receiving glucocorticoids and 85% biologic disease-modifying antirheumatic drugs (including 6 taking abatacept [ABA] and 4 taking rituximab [RTX]). The majority (95%) received the BNT162b2 vaccine and only one of them received the ChAdOx1 nCoV-19 vaccine. After the third dose, 91% of the patients presented detectable anti-SARS-CoV-2 IgG and 76% showed neutralizing activity. Compared to other treatments, ABA and RTX were associated with the absence of neutralizing activity in 4 out of 5 (80%) patients and lower titers of neutralizing antibodies (median 3, IQR 0-20 vs 8, IQR 4-128; P = 0.20). Specific T cell response was detected in 41% of all patients after the second dose, increasing to 71% after the third dose. The use of ABA was associated with a lower frequency of T cell response (33% vs 87%, P = 0.03). Conclusion. In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.Fil: Isnardi, Carolina A.. No especifíca;Fil: Cerda, Osvaldo L.. No especifíca;Fil: Landi, Margarita. Austral University Hospital; LiberiaFil: Cruces, Leonel Hernán. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Schneeberger, Emilce E.. No especifíca;Fil: Montoro, Claudia Calle. Austral University Hospital; LiberiaFil: Alfaro, María Agustina. No especifíca;Fil: Roldán, Brian M.. No especifíca;Fil: Gómez Vara, Andrea B.. No especifíca;Fil: Giorgis, Pamela. No especifíca;Fil: Ezquer, Roberto Alejandro. No especifíca;Fil: Crespo Rocha, María G. No especifíca;Fil: Reyes Gómez, Camila R.. No especifíca;Fil: de Los Ángeles Correa, Mária. No especifíca;Fil: Rosemffet, Marcos G.. No especifíca;Fil: Abarza, Virginia Carrizo. No especifíca;Fil: Pellet, Santiago Catalan. Austral University Hospital; LiberiaFil: Perandones, Miguel. No especifíca;Fil: Reimundes, Cecilia. Austral University Hospital; LiberiaFil: Longueira, Yesica Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Turk, Gabriela Julia Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Quiroga, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Laufer, Natalia Lorna. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Quintana, Rosana Maris. No especifíca;Fil: de la Vega, María Celina. No especifíca;Fil: Kreplak, Nicolás. No especifíca;Fil: Pifano, Marina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Maid, Pablo. Austral University Hospital; LiberiaFil: Pons Estel, Guillermo J.. No especifíca;Fil: Citera, Gustavo. No especifíca;J Rheumatol Publ Co2022-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/212994Isnardi, Carolina A.; Cerda, Osvaldo L.; Landi, Margarita; Cruces, Leonel Hernán; Schneeberger, Emilce E.; et al.; Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines; J Rheumatol Publ Co; Journal Of Rheumatology; 49; 12; 12-2022; 1385-13890315-162XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3899/jrheum.220469info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:02:05Zoai:ri.conicet.gov.ar:11336/212994instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:02:05.258CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
title Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
spellingShingle Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
Isnardi, Carolina A.
ARGENTINA
COVID-19
RHEUMATOID ARTHRITIS
SARS-COV-2
VACCINES
title_short Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
title_full Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
title_fullStr Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
title_full_unstemmed Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
title_sort Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines
dc.creator.none.fl_str_mv Isnardi, Carolina A.
Cerda, Osvaldo L.
Landi, Margarita
Cruces, Leonel Hernán
Schneeberger, Emilce E.
Montoro, Claudia Calle
Alfaro, María Agustina
Roldán, Brian M.
Gómez Vara, Andrea B.
Giorgis, Pamela
Ezquer, Roberto Alejandro
Crespo Rocha, María G
Reyes Gómez, Camila R.
de Los Ángeles Correa, Mária
Rosemffet, Marcos G.
Abarza, Virginia Carrizo
Pellet, Santiago Catalan
Perandones, Miguel
Reimundes, Cecilia
Longueira, Yesica Soledad
Turk, Gabriela Julia Ana
Quiroga, María Florencia
Laufer, Natalia Lorna
Quintana, Rosana Maris
de la Vega, María Celina
Kreplak, Nicolás
Pifano, Marina
Maid, Pablo
Pons Estel, Guillermo J.
Citera, Gustavo
author Isnardi, Carolina A.
author_facet Isnardi, Carolina A.
Cerda, Osvaldo L.
Landi, Margarita
Cruces, Leonel Hernán
Schneeberger, Emilce E.
Montoro, Claudia Calle
Alfaro, María Agustina
Roldán, Brian M.
Gómez Vara, Andrea B.
Giorgis, Pamela
Ezquer, Roberto Alejandro
Crespo Rocha, María G
Reyes Gómez, Camila R.
de Los Ángeles Correa, Mária
Rosemffet, Marcos G.
Abarza, Virginia Carrizo
Pellet, Santiago Catalan
Perandones, Miguel
Reimundes, Cecilia
Longueira, Yesica Soledad
Turk, Gabriela Julia Ana
Quiroga, María Florencia
Laufer, Natalia Lorna
Quintana, Rosana Maris
de la Vega, María Celina
Kreplak, Nicolás
Pifano, Marina
Maid, Pablo
Pons Estel, Guillermo J.
Citera, Gustavo
author_role author
author2 Cerda, Osvaldo L.
Landi, Margarita
Cruces, Leonel Hernán
Schneeberger, Emilce E.
Montoro, Claudia Calle
Alfaro, María Agustina
Roldán, Brian M.
Gómez Vara, Andrea B.
Giorgis, Pamela
Ezquer, Roberto Alejandro
Crespo Rocha, María G
Reyes Gómez, Camila R.
de Los Ángeles Correa, Mária
Rosemffet, Marcos G.
Abarza, Virginia Carrizo
Pellet, Santiago Catalan
Perandones, Miguel
Reimundes, Cecilia
Longueira, Yesica Soledad
Turk, Gabriela Julia Ana
Quiroga, María Florencia
Laufer, Natalia Lorna
Quintana, Rosana Maris
de la Vega, María Celina
Kreplak, Nicolás
Pifano, Marina
Maid, Pablo
Pons Estel, Guillermo J.
Citera, Gustavo
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv ARGENTINA
COVID-19
RHEUMATOID ARTHRITIS
SARS-COV-2
VACCINES
topic ARGENTINA
COVID-19
RHEUMATOID ARTHRITIS
SARS-COV-2
VACCINES
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Objective. The aim of this study was to assess the immune response after a third dose of SARS-CoV-2 vaccine in patients with rheumatoid arthritis (RA) with undetectable antibody titers after the primary regimen of 2 doses. Methods. Patients with RA with no seroconversion after 2 doses of SARS-CoV-2 vaccine and who received a third dose of either an mRNA or vector-based vaccine were included. Anti-SARS-CoV-2 IgG antibodies, neutralizing activity, and T cell responses were assessed after the third dose. Results. A total of 21 nonresponder patients were included. At the time of vaccination, 29% were receiving glucocorticoids and 85% biologic disease-modifying antirheumatic drugs (including 6 taking abatacept [ABA] and 4 taking rituximab [RTX]). The majority (95%) received the BNT162b2 vaccine and only one of them received the ChAdOx1 nCoV-19 vaccine. After the third dose, 91% of the patients presented detectable anti-SARS-CoV-2 IgG and 76% showed neutralizing activity. Compared to other treatments, ABA and RTX were associated with the absence of neutralizing activity in 4 out of 5 (80%) patients and lower titers of neutralizing antibodies (median 3, IQR 0-20 vs 8, IQR 4-128; P = 0.20). Specific T cell response was detected in 41% of all patients after the second dose, increasing to 71% after the third dose. The use of ABA was associated with a lower frequency of T cell response (33% vs 87%, P = 0.03). Conclusion. In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.
Fil: Isnardi, Carolina A.. No especifíca;
Fil: Cerda, Osvaldo L.. No especifíca;
Fil: Landi, Margarita. Austral University Hospital; Liberia
Fil: Cruces, Leonel Hernán. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Schneeberger, Emilce E.. No especifíca;
Fil: Montoro, Claudia Calle. Austral University Hospital; Liberia
Fil: Alfaro, María Agustina. No especifíca;
Fil: Roldán, Brian M.. No especifíca;
Fil: Gómez Vara, Andrea B.. No especifíca;
Fil: Giorgis, Pamela. No especifíca;
Fil: Ezquer, Roberto Alejandro. No especifíca;
Fil: Crespo Rocha, María G. No especifíca;
Fil: Reyes Gómez, Camila R.. No especifíca;
Fil: de Los Ángeles Correa, Mária. No especifíca;
Fil: Rosemffet, Marcos G.. No especifíca;
Fil: Abarza, Virginia Carrizo. No especifíca;
Fil: Pellet, Santiago Catalan. Austral University Hospital; Liberia
Fil: Perandones, Miguel. No especifíca;
Fil: Reimundes, Cecilia. Austral University Hospital; Liberia
Fil: Longueira, Yesica Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Turk, Gabriela Julia Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Quiroga, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Laufer, Natalia Lorna. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Quintana, Rosana Maris. No especifíca;
Fil: de la Vega, María Celina. No especifíca;
Fil: Kreplak, Nicolás. No especifíca;
Fil: Pifano, Marina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Maid, Pablo. Austral University Hospital; Liberia
Fil: Pons Estel, Guillermo J.. No especifíca;
Fil: Citera, Gustavo. No especifíca;
description Objective. The aim of this study was to assess the immune response after a third dose of SARS-CoV-2 vaccine in patients with rheumatoid arthritis (RA) with undetectable antibody titers after the primary regimen of 2 doses. Methods. Patients with RA with no seroconversion after 2 doses of SARS-CoV-2 vaccine and who received a third dose of either an mRNA or vector-based vaccine were included. Anti-SARS-CoV-2 IgG antibodies, neutralizing activity, and T cell responses were assessed after the third dose. Results. A total of 21 nonresponder patients were included. At the time of vaccination, 29% were receiving glucocorticoids and 85% biologic disease-modifying antirheumatic drugs (including 6 taking abatacept [ABA] and 4 taking rituximab [RTX]). The majority (95%) received the BNT162b2 vaccine and only one of them received the ChAdOx1 nCoV-19 vaccine. After the third dose, 91% of the patients presented detectable anti-SARS-CoV-2 IgG and 76% showed neutralizing activity. Compared to other treatments, ABA and RTX were associated with the absence of neutralizing activity in 4 out of 5 (80%) patients and lower titers of neutralizing antibodies (median 3, IQR 0-20 vs 8, IQR 4-128; P = 0.20). Specific T cell response was detected in 41% of all patients after the second dose, increasing to 71% after the third dose. The use of ABA was associated with a lower frequency of T cell response (33% vs 87%, P = 0.03). Conclusion. In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response.
publishDate 2022
dc.date.none.fl_str_mv 2022-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/212994
Isnardi, Carolina A.; Cerda, Osvaldo L.; Landi, Margarita; Cruces, Leonel Hernán; Schneeberger, Emilce E.; et al.; Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines; J Rheumatol Publ Co; Journal Of Rheumatology; 49; 12; 12-2022; 1385-1389
0315-162X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/212994
identifier_str_mv Isnardi, Carolina A.; Cerda, Osvaldo L.; Landi, Margarita; Cruces, Leonel Hernán; Schneeberger, Emilce E.; et al.; Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines; J Rheumatol Publ Co; Journal Of Rheumatology; 49; 12; 12-2022; 1385-1389
0315-162X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.3899/jrheum.220469
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv J Rheumatol Publ Co
publisher.none.fl_str_mv J Rheumatol Publ Co
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269736076836864
score 13.13397